| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Natural polyphenol
|
|---|---|
| ln Vitro |
(+)-epicatechin is the enantiomer of (-)Epicatechin.
|
| References | |
| Additional Infomation |
(+)-Epicatechin is a catechin belonging to the flavanoids, with five hydroxyl substituents at positions 3, 3', 4', 5, and 7 (2S,3S-stereoisomers). It is a cyclooxygenase I inhibitor and a plant metabolite. It is both a catechin and a polyphenol. It is the enantiomer of (-)-epicatechin.
(+)-Epicatechin has been reported to exist in Rosa laevigata, Pavetta owariensis, and several other organisms with relevant data. Phytochemical studies of the stems of Millettia dielsiana Harms ex Diels isolated a new isoflavone glycoside—millettia glycoside A (1)—and 14 known compounds (2-15). Their chemical structures were determined by combining infrared spectroscopy, nuclear magnetic resonance spectroscopy, mass spectrometry, and optical rotation analysis, and by comparing with literature data. Ethanol extracts and several isolated compounds exerted inflammatory effects in lipopolysaccharide (LPS)-stimulated mouse RAW264.7 macrophages by inducing nitric oxide (NO) production. [1] In summary, a novel isoflavone glycoside, mildiside A (1), and 14 phenolic derivatives (2–15) were identified from the stems of M. dielsiana. Their structures were elucidated by spectroscopic analysis and comparison with previously reported physicochemical data. Most of the isolated compounds were phenolic derivatives, consistent with previous reports on other Millettia species. The active ingredients isolated from this plant may have the potential to treat inflammation-related diseases. [1] |
| Molecular Formula |
C15H14O6
|
|---|---|
| Molecular Weight |
290.27
|
| Exact Mass |
290.079
|
| Elemental Analysis |
C, 62.07; H, 4.86; O, 33.07
|
| CAS # |
35323-91-2
|
| Related CAS # |
(-)-Epicatechin;490-46-0
|
| PubChem CID |
182232
|
| Appearance |
White to off-white solid
|
| Density |
1.593 g/cm3
|
| Boiling Point |
630.4ºC at 760 mmHg
|
| Melting Point |
235 - 237 °C
|
| Flash Point |
335ºC
|
| Index of Refraction |
1.741
|
| Source |
Originated from plants: other families
|
| LogP |
1.546
|
| tPSA |
110.38
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC(=C(C=C1[C@H]2[C@H](CC3=C(C=C(C=C3O2)O)O)O)O)O
|
| InChi Key |
PFTAWBLQPZVEMU-ZFWWWQNUSA-N
|
| InChi Code |
InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m0/s1
|
| Chemical Name |
(2S,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
|
| Synonyms |
(+)-Epicatechin; 35323-91-2; ent-Epicatechin; d-Epicatechin; (+)-epicatechol; (2S,3S)-2-(3,4-dihydroxyphenyl)chroman-3,5,7-triol; (2S,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; Catechin C;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~172.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4451 mL | 17.2253 mL | 34.4507 mL | |
| 5 mM | 0.6890 mL | 3.4451 mL | 6.8901 mL | |
| 10 mM | 0.3445 mL | 1.7225 mL | 3.4451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04386304
Conditions:Becker Muscular DystrophyLink: https://clinicaltrials.gov/ct2/show/NCT02964377
Conditions:Duchenne Muscular DystrophyLink: https://clinicaltrials.gov/ct2/show/NCT02660112
Conditions:Friedreich's Ataxia
Title:Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
Status:Completed
updateDate:2017-04-17
Ctid:NCT02330276
Link: https://clinicaltrials.gov/ct2/show/NCT02330276
Conditions:Pre-diabetesProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
